STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Corcept Therapeutics (CORT) director logs 10,000-share indirect sale under 10b5-1 plan

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics director James N. Wilson reported indirect sales of 10000 shares of common stock on July 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust at weighted-average prices between $86.7777 and $89.4881 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.

After these sales, that trust held 1093464.0000 shares of common stock, while separate 2025 Grantor Retained Annuity Trusts for James and Pamela Wilson each held 200000.0000 shares indirectly; Wilson has voting power over the trust shares and disclaims beneficial ownership except to the extent of his pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider WILSON JAMES N
Role Director
Sold 10,000 shs ($883K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F6 1,079 $86.7777 $94K
Sale Common Stock F1, F3, F6 3,969 $87.7356 $348K
Sale Common Stock F1, F4, F6 2,974 $88.8105 $264K
Sale Common Stock F1, F5, F6 1,978 $89.4881 $177K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,084,543 shares (Indirect, James N. Wilson and Pamela D. Wilson Trust); Common Stock — 200,000 shares (Indirect, James N. Wilson 2025 Grantor Retained Annuity Trust); Common Stock — 200,000 shares (Indirect, Pamela D. Wilson 2025 Grantor Retained Annuity Trust)
Footnotes (6)
  1. F1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
  2. F2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.20 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.31 to $89.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F6. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Shares sold 10000 shares Total common shares sold indirectly on 2026-07-15
Weighted-average sale price block 1 $89.4881 per share 1978 shares sold indirectly by James N. Wilson and Pamela D. Wilson Trust
Weighted-average sale price block 2 $88.8105 per share 2974 shares sold indirectly by James N. Wilson and Pamela D. Wilson Trust
Weighted-average sale price block 3 $87.7356 per share 3969 shares sold indirectly by James N. Wilson and Pamela D. Wilson Trust
Weighted-average sale price block 4 $86.7777 per share 1079 shares sold indirectly by James N. Wilson and Pamela D. Wilson Trust
Indirect trust holdings after sales 1093464.0000 shares Common shares held by James N. Wilson and Pamela D. Wilson Trust after 2026-07-15 transactions
Pamela D. Wilson 2025 GRAT holdings 200000.0000 shares Common shares held indirectly by Pamela D. Wilson 2025 Grantor Retained Annuity Trust
James N. Wilson 2025 GRAT holdings 200000.0000 shares Common shares held indirectly by James N. Wilson 2025 Grantor Retained Annuity Trust
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Grantor Retained Annuity Trust financial
"Pamela D. Wilson 2025 Grantor Retained Annuity Trust reported indirect holdings of common stock"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold"
pecuniary interest financial
"disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest"
indirect ownership financial
"Ownership type is reported as indirect due to shares held by various trusts"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did CORT director James N. Wilson report?
Director James N. Wilson reported indirect sales of 10000 shares of Corcept Therapeutics common stock on July 15, 2026. The shares were sold by the James N. Wilson and Pamela D. Wilson Trust at weighted-average prices between $86.7777 and $89.4881 per share.

At what prices were the 10000 CORT shares sold by the Wilson trust?
The 10000 shares were sold at weighted-average prices of $89.4881, $88.8105, $87.7356, and $86.7777 per share. Each price corresponds to a separate trade block executed indirectly through the James N. Wilson and Pamela D. Wilson Trust.

How many CORT shares does the Wilson trust hold after the reported sales?
Following the reported transactions, the James N. Wilson and Pamela D. Wilson Trust held 1093464.0000 shares of Corcept Therapeutics common stock indirectly. This post-transaction balance is reported after the aggregate sale of 10000 shares on July 15, 2026.

Were James N. Wilson’s CORT share sales made under a Rule 10b5-1 plan?
Yes. The filing states the sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. Such pre-arranged plans structure trading in advance and can reduce the informational significance of transaction timing.

What indirect CORT holdings are reported in the 2025 Grantor Retained Annuity Trusts?
The filing reports 200000.0000 shares of Corcept Therapeutics common stock held indirectly by the Pamela D. Wilson 2025 Grantor Retained Annuity Trust and another 200000.0000 shares held by the James N. Wilson 2025 Grantor Retained Annuity Trust as of July 15, 2026.

Does James N. Wilson beneficially own all CORT shares held by the Wilson trust?
No. He has voting power over shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements but disclaims beneficial ownership of those shares, except to the extent of his pecuniary interest in them, as disclosed in the footnotes.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WILSON JAMES N
(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CALIFORNIA 94065
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/15/2026S(1)1,079D$86.7777(2)1,093,464IJames N. Wilson and Pamela D. Wilson Trust(6)
Common Stock07/15/2026S(1)3,969D$87.7356(3)1,089,495IJames N. Wilson and Pamela D. Wilson Trust(6)
Common Stock07/15/2026S(1)2,974D$88.8105(4)1,086,521IJames N. Wilson and Pamela D. Wilson Trust(6)
Common Stock07/15/2026S(1)1,978D$89.4881(5)1,084,543IJames N. Wilson and Pamela D. Wilson Trust(6)
Common Stock200,000IJames N. Wilson 2025 Grantor Retained Annuity Trust
Common Stock200,000IPamela D. Wilson 2025 Grantor Retained Annuity Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.20 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.31 to $89.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
6. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR